Sanofi took a €4.7b hit to statutory profit in the last twelve months because of unusual items. The market still liked the recent earnings report, which points to earnings power that looks better than the headline number suggests.
The €4.7b reduction came in the year to September 2026, when unusual items cut into statutory profit. That left EPS lower over the same period, even though the underlying earnings potential is described as as good as, or possibly better than, the statutory figure implies.
Sanofi and the €4.7b charge
€4.7b is the scale of the distortion Sanofi absorbed during the last twelve months. Unusual items drove that hit, and the report says those items are often not repeated, which is why the statutory result may not be the best read on the business’s recurring power.
3 warning signs were also flagged for Sanofi. That does not erase the earnings report, but it gives investors a narrower read-through: the headline profit was soft, while the underlying picture still drew a favorable response.
EPS and earnings power
EPS shrunk in the last twelve months, so the headline trend was weaker than the market’s reaction suggested. The contrast is the point: the share of profit assigned to each unit of capital moved down even as the market responded positively to the recent earnings report.
In the year to September 2026, that gap between statutory profit and underlying earnings matters more than the headline number alone. If the unusual items do not recur, the implied earnings base may look sturdier than the reported profit line.
Simply Wall St and Sanofi
Simply Wall St’s read is that Sanofi’s statutory earnings do not fully reflect its underlying profit potential. For readers, the practical takeaway is to separate the one-off drag from the operating trend and to focus on whether future reports continue to show earnings strength beneath the profit headline.
The open question is what the unusual items were that reduced Sanofi’s profit by €4.7b. Until that is spelled out, the safest interpretation is that the latest result may understate the company’s recurring earning power rather than define it.
